Metronome LLC v. Axcentria Pharmaceuticals: Cannabis Topical Patent Dismissed
Metronome LLC filed suit against Axcentria Pharmaceuticals in the District of Delaware, asserting US10653736B2 covering cannabis-derived topical drug products. The case resolved in just 70 days via voluntary dismissal without prejudice under Rule 41(a)(1)(A)(i) — before Axcentria filed any answer or dispositive motion.
Cannabis topical patent suit ends before defendant responds
On September 24, 2025, Metronome LLC filed a patent infringement action against Axcentria Pharmaceuticals LLC in the United States District Court for the District of Delaware (Case No. 1:25-cv-01185) before Judge Colm F. Connolly. The asserted patent, US10653736B2, covers topical treatments incorporating cannabis sp. derived botanical drug products — a rapidly evolving area of pharmaceutical IP as cannabis-derived therapeutics move toward regulatory acceptance.
On December 3, 2025 — just 70 days after filing — Metronome filed a notice of voluntary dismissal pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), dismissing the action without prejudice. The notice specifically confirmed that Axcentria had not yet answered the complaint or moved for summary judgment, satisfying the procedural precondition for a unilateral Rule 41 dismissal. No court order was required, and no merits determination was reached.
The brevity of the litigation and the absence of any responsive pleading suggests the case may have been resolved through out-of-court negotiations, a licensing agreement, or a strategic reassessment of enforcement priorities — though the public record is silent on the underlying motivation. The without-prejudice designation is commercially significant: Metronome preserves the right to refile against Axcentria or pursue other defendants on the same patent, leaving the IP landscape in this segment unsettled.
Filing to Voluntary dismissal in 70 days
Case closed in 70 days — well below median patent case duration in D. Del.
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): unilateral dismissal before answer
Federal Rule of Civil Procedure 41(a)(1)(A)(i) allows a plaintiff to dismiss an action without a court order by filing a notice of dismissal before the defendant serves an answer or a motion for summary judgment. Because Axcentria had not yet responded, Metronome could exit the case unilaterally. The dismissal takes effect immediately upon filing — no judicial approval is required and no merits ruling is made.
No court order requiredWithout prejudice: the distinction the public record confirms
The notice expressly states ‘without prejudice,’ meaning Metronome is not barred from refiling the same claims against Axcentria or asserting US10653736B2 against other parties. A with-prejudice dismissal would have permanently extinguished those claims. The public record confirms the without-prejudice designation; the underlying commercial reason — whether settlement, licensing, or strategy — is not disclosed in the court filings.
Refiling right preservedAxcentria avoids a merits ruling — but faces residual risk
Axcentria Pharmaceuticals was never required to answer the complaint, file invalidity contentions, or engage in discovery. While the dismissal removes the immediate litigation burden, the without-prejudice designation means Axcentria cannot treat this as a final resolution. The patent remains in force and Metronome retains full enforcement rights, leaving Axcentria’s products potentially exposed to future action on the same patent.
No merits immunity gainedUS10653736B2 remains an active enforcement risk for the cannabis topical sector
The voluntary dismissal without prejudice leaves US10653736B2 fully intact and enforceable. Competitors and manufacturers in the cannabis-derived topical drug product space should treat this patent as an ongoing risk. The speed of resolution — 70 days with no answer filed — is consistent with either a rapid licensing arrangement or a strategic hold while Metronome identifies broader enforcement targets. Freedom-to-operate analysis against this patent remains advisable.
Patent remains enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Metronome LLC | Company | Pharmaceutical IP licensor — holder of US10653736B2 covering cannabis-derived topical drug productsSearch in Eureka ↗ |
| Defendant | Axcentria Pharmaceuticals, LLC | Company | Axcentria Pharmaceuticals LLC — specialty pharmaceutical company targeted over cannabis topical productsSearch in Eureka ↗ |
| Plaintiff counsel | Brian E. Lutness | Attorney | Counsel for Metronome LLCSearch in Eureka ↗ |
| Plaintiff law firm | Silverman, McDonald & Friedman | Law Firm | Representing Metronome LLCSearch in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The voluntary dismissal notice invokes Rule 41(a)(1)(A)(i) and explicitly confirms the without-prejudice designation, which is legally operative without any court order. The filing’s confirmation that Axcentria had not answered or moved for summary judgment is procedurally significant: it establishes the preconditions for unilateral dismissal were met. No claim construction, validity ruling, or infringement finding was issued. The patent’s enforceability is entirely unaffected, and Metronome’s litigation posture against this defendant — or others — remains open.
US10653736B2 — Cannabis-derived topical botanical drug product treatments
US10653736B2, filed under application number US16/257389, protects topical treatments incorporating cannabis species-derived botanical drug products. The patent sits at the intersection of pharmaceutical formulation and cannabis-derived active ingredient delivery — an area that gained significant regulatory attention as the FDA began developing frameworks for botanical drug submissions. The patent’s grant reflects successful prosecution of claims covering a specific category of topically applied cannabis-derived therapeutics, distinguishing them from both systemic cannabis formulations and conventional topical drug products.
Strategically, US10653736B2 represents meaningful IP in a sector where patent portfolios are still being established and claim scope is frequently contested. As cannabis-derived pharmaceutical products move closer to mainstream regulatory approval — including botanical drug pathways — ownership of core formulation patents becomes a significant commercial asset. Any company developing, manufacturing, or distributing topical products incorporating cannabis-derived botanical ingredients should assess exposure to this patent’s claim scope, particularly given the patentee’s demonstrated willingness to file enforcement actions in Delaware.
Should your cannabis topical product be assessed against US10653736B2?
R&D teams and product managers developing topical drug products that incorporate cannabis species-derived botanical drug substances should treat US10653736B2 as a live freedom-to-operate concern. The patent remains fully enforceable following the voluntary dismissal, and the without-prejudice posture of Metronome’s exit signals ongoing enforcement intent. Companies commercialising cannabis topicals — including dermatological, analgesic, and anti-inflammatory applications — face non-trivial infringement exposure if their formulations fall within the patent’s claim scope.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US10653736B2 against your specific formulation parameters, identify prior art that may support an IPR petition, and surface related patents in Metronome’s portfolio that could affect adjacent product lines. For companies in the cannabis pharmaceutical space, an Eureka-powered FTO analysis provides the structured claim comparison and prosecution history review needed to make defensible product-clearance decisions before launch or investment.
Run a freedom-to-operate analysis on US10653736B2 to assess your product’s exposure
Run FTO in Eureka →Similar cannabis pharmaceutical patent cases in D. Del. and related courts
Cases involving cannabis-derived pharmaceutical patent enforcement in the District of Delaware and related district courts — including Rule 41 voluntary dismissals and botanical drug IP disputes.
What this case signals for the cannabis pharmaceutical IP landscape
A 70-day lifecycle and pre-answer exit raises questions about enforcement strategy and licensing leverage across cannabis topical therapeutics.
Pre-answer dismissals often signal off-record licensing or strategic pivots
When a plaintiff exits before the defendant even responds, it typically suggests one of three scenarios: a licensing deal was reached quickly, the plaintiff identified a procedural or standing issue, or enforcement resources are being redirected. In cannabis pharma, where patent portfolios are still maturing, early licensing discussions are common. The public record does not confirm which applies here.
Without-prejudice dismissals keep competitive pressure alive
A without-prejudice exit is not a retreat — it preserves all of the plaintiff’s enforcement rights. Companies operating in the cannabis-derived topical drug product space should note that US10653736B2 is still live and that the same patentee can refile against Axcentria or target other market participants. Monitoring Metronome’s future filings is advisable for anyone in this sector.
Metronome v Axcentria — key questions answered
Metronome LLC dismissed the case under Rule 41(a)(1)(A)(i), which permits a plaintiff to exit unilaterally before the defendant answers. The without-prejudice designation means Metronome retains the right to refile the same infringement claims against Axcentria or assert US10653736B2 against other defendants. No merits ruling was issued and the patent remains fully enforceable.
The asserted patent is US10653736B2 (application number US16/257389), which covers topical treatments incorporating cannabis species-derived botanical drug products. The case involves Axcentria’s topical cannabis-derived pharmaceutical products as the accused product category.
The public record does not disclose the reason. A voluntary pre-answer dismissal of this speed is consistent with several possibilities: an off-record licensing or settlement agreement, a strategic decision to refile with amended claims or additional defendants, or identification of a procedural issue. None of these scenarios can be confirmed from the available court filings.
No. Because the dismissal was entered without prejudice, Axcentria received no immunity from future infringement claims on US10653736B2. Metronome may refile against Axcentria at any time subject to applicable statutes of limitations. Axcentria’s products remain potentially exposed, and the company would benefit from conducting a freedom-to-operate analysis and assessing IPR petition options against the asserted patent.
The case was filed in the United States District Court for the District of Delaware and assigned to Judge Colm F. Connolly. The case was closed on December 3, 2025, approximately 70 days after filing on September 24, 2025, upon Metronome’s filing of a voluntary notice of dismissal without prejudice.
PatSnap Eureka searches patents and litigation data to answer instantly.